Sector News

GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M

October 22, 2022
Life sciences

It’s a remarkable honeymoon GSK and Samsung Biologics are enjoying. Already linked by one major deal, the companies have furthered their relationship with a larger contract.

In this one, U.K. drugmaker GSK will pay (PDF) Korean contract manufacturer Samsung Biologics $296 million in a deal that runs through 2030.

A regulatory filing that revealed the contract did not specify which medicines Samsung will produce. It did show that the contract figure adds up to nearly 27% of Samsung’s sales revenue in 2021.

The deal comes as Samsung is opening what it has dubbed its “Super Plant”—the fourth manufacturing facility at the company’s sprawling complex in Incheon, South Korea. Samsung spent $2 billion to build the Super Plant. In all, the company’s plans call for six factories to be constructed at the site as Samsung is making an ambitious push to become a major player in the CDMO arena.

In May of 2020, GSK and Samsung hooked up on a $231 million, eight-year deal to produce biologic products including lupus drug Benlysta.

That deal came on the heels of Samsung pairing with Vir Biotechnology on a $362 million contract to produce antibodies. That agreement also involved GSK as the company partnered with Vir in a COVID-19 antibody program.

By Kevin Dunleavy

Source: fiercepharma.com

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach